Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Full description
Study Design :
This open label (all participants know the identity of the study drug), multicenter (more than one study site), first-in-human study consisting of 2 parts. Part 1 is a dose escalation and Part 2 is a dose expansion cohort. Part 1 has been completed.
Part 2 new patient populations examined:
For these new patient populations, Part 2 will further characterize the safety and tolerability of the selected dose level of zenocutuzumab (MCLA-128), as well as assessment of CBR, defined as the proportion of patients with a CR, PR or durable SD (SD for at least 24 weeks in duration). For the new patient populations, overall response rate (ORR) and duration of response (DOR) will be described.
The study consists of 3 periods: Screening period (up to 28 days prior to the first dose of study drug); Treatment period (treatment cycles of 28 days); and Follow Up period (through 30 days after the last dose and quarterly checks for survival data for up to 2 years). Participants' safety will be monitored throughout the study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
At least one measurable lesion according to RECIST v1.1 OR evaluable disease for a limited number of patients (up to 15) in Group H;
Performance status of ECOG 0 - 2;
Estimated life expectancy of at least 12 weeks;
Toxicities incurred as a result of previous anti-cancer therapy resolved to ≤Grade 1;
Treatment with anti-cancer medication or investigational drugs within the following intervals before the first dose of MCLA-128:
Recovery from major surgery or other complication to ≤ Grade 2 or baseline ;
Absolute neutrophil count ≥1.5 x 109/L without colony stimulating factor support for at least 7 days prior to screening;
Platelets ≥75 x 109/L without transfusion support for at least 7 days prior to screening;
Hemoglobin ≥8 g/dL or ≥5 mmol/L;
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤3 x upper limit of normal (ULN) and total bilirubin ≤1.5 x ULN; in cases of metastatic liver involvement, ALT/AST ≤5 x ULN and total bilirubin ≤2 x ULN will be allowed; in cases of antecedents of Gilbert's syndrome when total bilirubin ≤3.0 x ULN or direct bilirubin ≤1.5 x ULN will be allowed;
Estimated glomerular filtration rate (GFR) of >30 mL/min
Able to provide a tumor biopsy sample (fresh strongly preferred or else archival);
Not pregnant or nursing
Fertile patients must use effective contraception during and for 6 month after completion of study therapy;
Patients must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the Investigator, would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy or no satisfactory alternative treatment options are available;
Locally-advanced unresectable or metastatic solid tumor malignancy with documented NRG1 gene fusion, identified through molecular assays such as next generation sequencing-based assays [DNA or RNA], as routinely performed at CLIA or other similarly-certified laboratories.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
250 participants in 3 patient groups
Loading...
Central trial contact
Merus Inquiries
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal